Objective: To define changes in cutaneous P-SYN quantitation over 18 months in patients with Parkinson’s disease (PD) and isolated REM sleep behavior disorder (iRBD).To define changes in cutaneous P-SYN quantitation over 18 months in patients with Parkinson’s disease (PD) and isolated REM sleep behavior disorder (iRBD).
Background: Parkinson’s disease (PD) is characterized by progressive pathological alpha-synuclein (P-SYN) deposition in the central and peripheral nervous system. Skin biopsy has demonstrated high accuracy for the detection of peripheral P-SYN in patients with PD. Recent advances now allow for quantitation of peripheral P-SYN, although longitudinal studies in PD have not been conducted.
Method: After consent, participants with PD of Hoehn and Yahr stages 1, 2, 3 and iRBD completed neurological examinations, medical history, cognitive evaluation, motor assessments, olfactory testing (BSIT), orthostatic vitals, and neurodegenerative disease questionnaires. Skin biopsies taken from the distal leg, distal thigh, and posterior cervical sites were performed on all participants with blinded quantitation of P-SYN. Participants will return for follow-up visits at 6-month intervals following the baseline visit.
Results: 108 patients completed baseline testing (PD stage I: n=27, 65±7 years, 15 female; PD stage II: n=27, 67±9 years, 12 female; PD stage III: n=26, 74±8 years, 15 female; RBD: n=28, 65±9 years, 7 female). Baseline P-SYN results were available in all patients and 98/108 were P-SYN positive. Analysis by disease severity revealed 26/28 iRBD patients were P-SYN positive, 24/27 in PD Stage I, 25/27 in PD Stage II, and 23/26 in Stage III patients were P-SYN positive. P-SYN quantitative assessment correlated with greater motor impairment, indicated by the UPDRS Pt. 3 (r=0.22, p=0.05). 50 patients completed 6-month follow-up visits and had available P-SYN results at the time of abstract submission (11 PD stage I, 22 PD stage II, 10 PD stage II, and 7 iRBD). Increases in P-SYN were observed in the majority of patients.
Conclusion: Cutaneous P-SYN was present in skin samples from patients with iRBD and in PD across Hoehn and Yahr stages 1-3. Preliminary data suggests a correlation between quantitative measures of P-SYN and disease severity. Longitudinal follow-up data collection is ongoing and will be reported at the 2026 MDS meeting.
To cite this abstract in AMA style:
R. Freeman, T. Levine, J. Parent, S. Marcotte, B. Bellaire, M. Duval, C. Gibbons. The Syn-Q Study: Quantification of phosphorylated alpha-synuclein in patients with Parkinson’s disease and REM sleep behavior disorder [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/the-syn-q-study-quantification-of-phosphorylated-alpha-synuclein-in-patients-with-parkinsons-disease-and-rem-sleep-behavior-disorder/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-syn-q-study-quantification-of-phosphorylated-alpha-synuclein-in-patients-with-parkinsons-disease-and-rem-sleep-behavior-disorder/